Clinical Trials Logo
  1. Home
  2. Neoplasms Pancreatic
  3. NCT05547074

A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma

Neoplasms Pancreatic Clinical Trial

Official title:
Development and Validation of a New Prognostic Score Model Combining TNM Stage With Immune Risk Factors for Postoperative Pancreatic Ductal Adenocarcinoma

Clinical Trial Summary

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05547074
Study type Observational
Source Zhejiang University
Contact
Status Completed
Phase
Start date September 1, 2019
Completion date August 31, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT02973217 - Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04161417 - Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer N/A
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Terminated NCT04176952 - PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2